Aranesp Injection
PDF Leaflet Revision Date: 07 October 2020
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of symptomatic anaemia in chronic renal failure and cancer patients receiving chemotherapy.
Dosage (summary)
Initial dose: 0.45 u03bcg/kg once weekly or 0.75 u03bcg/kg every two weeks; adjust based on haemoglobin response.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Caution in pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Ciclosporin
- Tacrolimus
Contraindications
- Hypersensitivity
- Poorly controlled hypertension
Common side effects
- Hypertension
- Stroke
- Thromboembolic events
- Convulsions
- Allergic reactions
Counselling Points
- Monitor for signs of allergic reactions
- Rotate injection sites
- Report any unusual symptoms immediately
Serious warnings
- Increased risk of death and serious cardiovascular events
- Monitor blood pressure
- Avoid haemoglobin > 12 g/dl
Important Disclaimer
The Aranesp Injection professional information leaflet below is the property of Amgen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
